Cas:16052-67-8 ethyl 6-bromo-5-hydroxy-2-methyl-1H-indole-3-carboxylate manufacturer & supplier

Chemical Name:ethyl 6-bromo-5-hydroxy-2-methyl-1H-indole-3-carboxylate

CAS.NO:16052-67-8

Synonyms:6-bromo-5-hydroxy-2-methyl-indole-3-carboxylic acid ethyl ester;ethyl 6-bromo-5-hydroxy-2-methylindole-3-carboxylate;5-Hydroxy-6-brom-3-ethoxycarbonyl-2-methyl-indol;6-Bromo-5-hydroxy-2-methyl-1H-indole-3-carboxylic acid ethyl ester;6-Brom-5-hydroxy-2-methyl-indol-3-carbonsaeure-ethylester

Molecular Formula:C₁₂H₁₂BrNO₃

Molecular Weight:298.13300

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:62.32000

Exact Mass:297.00000

LogP:3.12110

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 6-bromo-5-hydroxy-2-methyl-indole-3-carboxylic acid ethyl ester chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,6-Brom-5-hydroxy-2-methyl-indol-3-carbonsaeure-ethylester physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,6-Bromo-5-hydroxy-2-methyl-1H-indole-3-carboxylic acid ethyl ester Use and application,6-Bromo-5-hydroxy-2-methyl-1H-indole-3-carboxylic acid ethyl ester technical grade,usp/ep/jp grade.

Related News: Refers to the active pharmaceutical ingredients used in the manufacture of original research drugs (patent drugs or innovative drugs). It mainly meets the needs of international original research drug companies and emerging biopharmaceutical companies for innovative drugs at various stages of clinical research, registration approval and commercialization of drugs. Contains advanced intermediates used in the manufacture of this drug substance that need to be regulated by regulatory authorities. ethyl 6-bromo-5-hydroxy-2-methyl-1H-indole-3-carboxylate manufacturer Rigosertib is a small molecule that inhibits cellular signaling in cancer cells by acting as a RAS mimetic. Current clinical development of rigosertib is centered upon the therapeutic management of MDS, a heterogeneous group of bone marrow disorders characterized by ineffective hematopoiesis that often develop into acute myeloid leukaemia (AML). ethyl 6-bromo-5-hydroxy-2-methyl-1H-indole-3-carboxylate supplier A number of UK citizens had trouble reaching the muster point in time for the first flight out because of road blocks and other restrictions in place in Wuhan. ethyl 6-bromo-5-hydroxy-2-methyl-1H-indole-3-carboxylate vendor A number of UK citizens had trouble reaching the muster point in time for the first flight out because of road blocks and other restrictions in place in Wuhan. ethyl 6-bromo-5-hydroxy-2-methyl-1H-indole-3-carboxylate factory By drawing these distinctions between APIs and the drugs themselves, manufacturers are able to specialize and pharmacists able to align generic equivalents with brand names.